Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation

D Bu, M Tarrio, E Maganto-Garcia… - … , and vascular biology, 2011 - Am Heart Assoc
D Bu, M Tarrio, E Maganto-Garcia, G Stavrakis, G Tajima, J Lederer, P Jarolim, GJ Freeman
Arteriosclerosis, thrombosis, and vascular biology, 2011Am Heart Assoc
Objective—Programmed cell death-1 (PD-1) is a member of the CD28 superfamily that
delivers negative signals on interaction with its 2 ligands, PD-L1 and PD-L2. We studied the
contribution of the PD-1 pathway to regulation of T cells that promote atherosclerotic lesion
formation and inflammation. Methods and Results—We show that compared with Ldlr−/−
control mice, Pd1−/− Ldlr−/− mice developed larger lesions with more abundant CD4+ and
CD8+ T cells and macrophages, accompanied by higher levels of serum tumor necrosis …
Objective
Programmed cell death-1 (PD-1) is a member of the CD28 superfamily that delivers negative signals on interaction with its 2 ligands, PD-L1 and PD-L2. We studied the contribution of the PD-1 pathway to regulation of T cells that promote atherosclerotic lesion formation and inflammation.
Methods and Results
We show that compared with Ldlr−/− control mice, Pd1−/−Ldlr−/− mice developed larger lesions with more abundant CD4+ and CD8+ T cells and macrophages, accompanied by higher levels of serum tumor necrosis factor-α. Iliac lymph node T cells from Pd1−/−Ldlr−/− mice proliferated more to αCD3 or oxidized low-density lipoprotein stimulation compared with controls. CD8+ T cells from Pd1−/−Ldlr−/− mice displayed more cytotoxic activity compared with controls in vivo and in vitro. Administration of a blocking anti-PD-1 antibody increased lesional inflammation in hypercholesterolemic Ldlr−/− mice with more lesional T cells and more activated T cells in paraaortic lymph nodes. The changes in lesional T-cell content when PD-1 was absent or blocked were also observed in bone marrow chimeric Ldlr−/− mice lacking PD-L1 and PD-L2 on hematopoietic cells.
Conclusion
PD-1 has an important role in downregulating proatherogenic T-cell responses, and blockade of this molecule for treatment of viral infections or cancer may increase risk of cardiovascular complications.
Am Heart Assoc